cGAS-STING pathway

Overview

The cGAS-STING pathway, comprising cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) and stimulator of interferon genes (STING), is a crucial component of the innate immune response. This pathway is activated in response to the presence of cytosolic DNA, which can originate from pathogens or damaged host cells. Upon activation, cGAS synthesizes cyclic dinucleotides that bind to STING, leading to the activation of downstream signaling cascades that promote the production of type I interferons and other proinflammatory cytokines. This response plays a significant role in anti-tumor immunity, making the cGAS-STING pathway a promising target for cancer immunotherapy.

Focus of Latest Publications

Recent publications demonstrate dual roles for the cGAS-STING pathway, positioning it as both a therapeutic target and an immune-activation platform depending on disease context. In cancer, the pathway emerges as a central mechanism for converting immunologically "cold" tumors into "hot" tumors by promoting dendritic cell maturation and recruiting CD8+ T cells. Multiple studies employ nanotechnology platforms—including black phosphorus nanosheets, manganese phosphate nanoparticles, copper nanoassemblies, and biomimetic nanorobots—designed to deliver cGAS-STING activators directly to tumors while simultaneously inducing immunogenic cell death through chemotherapy, photothermal effects, or cuproptosis. These hybrid nanotherapeutics consistently release metal ions (particularly Mn²⁺ and Zn²⁺) that lower the cGAS activation threshold, amplifying the innate immune response in breast cancer, cervical cancer, nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and colorectal cancer models.

At the molecular level, pathway activation is driven by cytosolic mitochondrial DNA accumulation through multiple injury routes: phototherapy-induced DNA damage, oxidative stress-triggered mtDNA leakage, topoisomerase inhibition-mediated DNA breaks, and radiation combined with metabolic dysfunction. Small-molecule strategies directly targeting pathway components show equal promise—Cdk4/6 inhibitors (palbociclib) unprotect micronuclei and trigger cGAS activation in esophageal cancer; AXL kinase inhibitors enhance cGAS activity in therapy-resistant tumors; and topoisomerase I inhibitor derivatives activate cGAS-STING alongside apoptosis. Cancer vaccine applications further exploit the pathway's immunogenicity: DNA-loaded manganese phosphate adjuvants and personalized tumor lysate-based nanovaccines activate dendritic cells and generate robust Th1 responses when combined with anti-TIGIT checkpoint blockade.

Conversely, in inflammatory and metabolic disorders, pathway inhibition emerges as the therapeutic goal. STING inhibition ameliorates diabetic retinopathy by reducing retinal pigment epithelial dysfunction and vascular changes in rodent models, while pharmacological cGAS inhibition or genetic cGAS knockout alleviates post-hemorrhagic hydrocephalus by suppressing microglial neuroinflammation and pyroptosis-dependent cytokine release. In metabolic dysfunction-associated steatohepatitis (MASH), the SIRT3–DsbA-L–TFAM axis naturally restrains cGAS-driven hepatocyte inflammation; loss of this axis promotes mitochondrial DNA leakage and exacerbates disease pathology. A dual cGAS/HDAC inhibitor (31h) demonstrates efficacy in murine inflammatory bowel disease and Aicardi-Goutieres syndrome by suppressing cGAS activity and preventing its accumulation through HDAC-mediated acetylation. Additionally, in vitiligo, blocking VDAC1 oligomerization prevents mtDNA release from dermal fibroblasts and inhibits cGAS-STING-driven innate immune activation, restoring epidermal repigmentation.

These findings establish the cGAS-STING pathway as a context-dependent therapeutic lever: in immunologically suppressed cancers, activation via metal-ion-delivering nanotherapeutics, DNA damage induction, or checkpoint inhibitor combinations generates durable antitumor immunity; in autoimmune and neuroinflammatory diseases, selective inhibition of cGAS, STING, or upstream mtDNA-release mechanisms reduces pathogenic inflammation. Future clinical translation will likely depend on precision matching of pathway modulation to tumor immunogenicity, inflammatory burden, and tissue-specific function.